Topic: asthma

Novartis headquarters

5. Fevipiprant

Novartis’ second entry on the list is fevipiprant, an orally active prostaglandin DP2 receptor antagonist which failed to improve lung function in two phase 3 trials involving patients with allergic asthma. It had previously been billed as another of Novartis’ blockbuster contenders.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.